UCB Agrees To Pay $34M Over Epilepsy Drug Labeling
The U.S. subsidiary of Belgian pharmaceuticals manufacturer UCB SA pled guilty Thursday to the off-label promotion of its epilepsy drug Keppra, and agreed to pay more than $34 million to resolve...To view the full article, register now.
Already a subscriber? Click here to view full article